Muneerah Aleissa, Pharm.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifungal Agents | 3 | 2023 | 759 | 0.700 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 233 | 0.650 |
Why?
|
| Alanine | 1 | 2020 | 613 | 0.590 |
Why?
|
| Mycoses | 1 | 2021 | 386 | 0.590 |
Why?
|
| Triazoles | 1 | 2021 | 904 | 0.510 |
Why?
|
| Aniline Compounds | 1 | 2021 | 1094 | 0.500 |
Why?
|
| Pyrazines | 1 | 2021 | 1206 | 0.490 |
Why?
|
| Cannabis | 1 | 2020 | 445 | 0.450 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2020 | 1421 | 0.330 |
Why?
|
| Antiviral Agents | 2 | 2024 | 3064 | 0.320 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 3620 | 0.250 |
Why?
|
| Acyclovir | 1 | 2024 | 267 | 0.210 |
Why?
|
| Echinocandins | 1 | 2023 | 53 | 0.210 |
Why?
|
| Virus Activation | 1 | 2024 | 322 | 0.200 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 3211 | 0.200 |
Why?
|
| Immunization, Secondary | 1 | 2024 | 372 | 0.190 |
Why?
|
| Immunoglobulin G | 2 | 2024 | 4570 | 0.190 |
Why?
|
| Opportunistic Infections | 1 | 2023 | 375 | 0.180 |
Why?
|
| Herpes Simplex | 1 | 2024 | 470 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2024 | 5713 | 0.180 |
Why?
|
| Simplexvirus | 1 | 2024 | 805 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 617 | 0.140 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2021 | 590 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 839 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 863 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2022 | 1376 | 0.120 |
Why?
|
| Retrospective Studies | 7 | 2023 | 81801 | 0.100 |
Why?
|
| Breast Feeding | 1 | 2020 | 1364 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 1905 | 0.100 |
Why?
|
| Knee Joint | 1 | 2020 | 1686 | 0.100 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2022 | 2676 | 0.090 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 3044 | 0.090 |
Why?
|
| Survival Rate | 1 | 2021 | 12870 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 8051 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 3836 | 0.060 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3118 | 0.050 |
Why?
|
| Lipopeptides | 1 | 2023 | 71 | 0.050 |
Why?
|
| Humans | 11 | 2024 | 768393 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2024 | 622 | 0.050 |
Why?
|
| Middle Aged | 4 | 2024 | 223491 | 0.050 |
Why?
|
| Aged | 3 | 2024 | 171562 | 0.050 |
Why?
|
| Female | 5 | 2024 | 397089 | 0.050 |
Why?
|
| Prognosis | 1 | 2021 | 30022 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2024 | 611 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 39407 | 0.040 |
Why?
|
| Adult | 6 | 2024 | 223640 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 437 | 0.040 |
Why?
|
| Pregnancy | 1 | 2020 | 30200 | 0.040 |
Why?
|
| Cell Count | 1 | 2022 | 1833 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 1082 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 2226 | 0.040 |
Why?
|
| Male | 4 | 2024 | 364902 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2023 | 1961 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 59686 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 60049 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1508 | 0.030 |
Why?
|
| Body Weight | 1 | 2023 | 4629 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2022 | 2389 | 0.020 |
Why?
|
| Overweight | 1 | 2023 | 2445 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 4785 | 0.020 |
Why?
|
| Critical Illness | 1 | 2021 | 2755 | 0.020 |
Why?
|
| Animals | 1 | 2020 | 169337 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 10267 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9433 | 0.020 |
Why?
|
| Incidence | 1 | 2022 | 21544 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 13084 | 0.010 |
Why?
|
| Risk Factors | 1 | 2022 | 74962 | 0.010 |
Why?
|